Technical Analysis for LQDA - Liquidia Technologies, Inc.

Grade Last Price % Change Price Change
F 2.77 -4.15% -0.12
LQDA closed down 4.15 percent on Thursday, April 22, 2021, on 46 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: May 10
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical LQDA trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
Upper Bollinger Band Walk Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 50 DMA Bullish -4.15%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.15%
Upper Bollinger Band Touch Strength -4.15%
50 DMA Resistance Bearish -2.12%
Pocket Pivot Bullish Swing Setup -2.12%
Older End-of-Day Signals for LQDA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Non-ADX 1,2,3,4 Pullback Entry about 4 hours ago
Rose Above Previous Day's High about 4 hours ago
Rose Above Upper Bollinger Band about 4 hours ago
Down 3% about 4 hours ago
Down 2 % about 4 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Liquidia Technologies, Inc. Description

Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Pharmaceutical Pharmaceutical Industry Pain Medication Hypertension Clinical Trial Opioid Uniform Pulmonary Arterial Hypertension Bupivacaine Inhaler Treprostinil

Is LQDA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.1
52 Week Low 2.34
Average Volume 1,105,035
200-Day Moving Average 3.97
50-Day Moving Average 2.85
20-Day Moving Average 2.66
10-Day Moving Average 2.70
Average True Range 0.20
ADX 15.5
+DI 24.85
-DI 14.43
Chandelier Exit (Long, 3 ATRs ) 2.42
Chandelier Exit (Short, 3 ATRs ) 2.95
Upper Bollinger Band 2.91
Lower Bollinger Band 2.40
Percent B (%b) 0.73
BandWidth 19.03
MACD Line 0.00
MACD Signal Line -0.04
MACD Histogram 0.0388
Fundamentals Value
Market Cap 119.95 Million
Num Shares 43.3 Million
EPS -2.51
Price-to-Earnings (P/E) Ratio -1.10
Price-to-Sales 18.55
Price-to-Book 1.96
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.07
Resistance 3 (R3) 3.10 3.04 3.02
Resistance 2 (R2) 3.04 2.96 3.02 3.00
Resistance 1 (R1) 2.90 2.91 2.87 2.87 2.99
Pivot Point 2.84 2.84 2.82 2.82 2.84
Support 1 (S1) 2.70 2.76 2.67 2.67 2.55
Support 2 (S2) 2.64 2.71 2.62 2.54
Support 3 (S3) 2.50 2.64 2.52
Support 4 (S4) 2.47